Company profile
Benitec Biopharma Inc.
NASDAQ: BNTC · Healthcare · Biotechnology
#1163 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 27GM —SS 55
v0.1 · 25/100 weight · pillars only
↑ balance-sheet leverage, Altman-Z · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$556.0k
Rev growth YoY (TTM)
-9366.7%
Net income (FY)
-$37.9M
Employees
19
as of 2026-09-13
Market cap
$418.8M
as of 2026-09-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02024
Net income-$37.9M-$37.9M2025
Operating income-$41.8M-$41.8M2025
Total assets$99.6M$99.6M2025
Liabilities$2.3M$2.3M2025
Equity$97.3M$97.3M2025
Revenue trend
FY2020 – FY2024 · USD
FY20
FY20
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2023
By product
License100%
By geography
Not disclosed.
The read
What is Benitec Biopharma Inc.’s revenue?
Benitec Biopharma Inc. booked $0 in FY2024 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Artiva Biotherapeutics, Inc.41DCapricor Therapeutics, Inc.57CNika Pharmaceuticals Inc.28DLarimar Therapeutics, Inc.38DRocket Pharmaceuticals, Inc.53DCompass Therapeutics, Inc.51DNeighbors
Alameda →Key facts
CEOJerel A. Banks
SectorHealthcare
IndustryBiotechnology
HeadquartersHayward, CA
ExchangeNASDAQ: BNTC
Employees19
IPO date2014-06-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.